

Figure 1




Figure 2

BEST AVAILABLE COPY




Figure 3

BEST AVAILABLE COPY




Figure 4

BEST AVAILABLE COPY




Figure 5

**Hematological changes of Irinotecan ± MSC in nude mice on day 22
after initial treatment of Irinotecan (24 h after third dose)**

<u>Treatment</u>	<u>WBC</u>	<u>RBC</u>	<u>HGB</u>	<u>HCT</u>	<u>MCV</u>	<u>MCH</u>	<u>MCHC</u>	<u>PLT</u>
<u>Control</u>	9.4±3.6	8.7±0.9	16.1±1.6	46.1±2.1	53.4±1.0	18.6±0.1	34.5±0.6	1118±415
MSC (0.2)*	10.3±4.5	9.1±0.5	16.8±0.7	49.4±2.4	54.0±1.0	18.4±0.7	34.0±0.7	756±231
Irinotecan (200)**	3.5±0.5	7.8±1.0	13.8±1.9	40.9±4.2	52.8±0.8	17.5±0.3	32.7±0.6	836±201
Irinotecan (200)** + MSC (0.2)*	8.2±3.1	8.5±0.5	15.4±0.7	44.8±1.8	52.8±1.5	18.0±0.5	34.0±0.6	1174±152

Figure 6




Figure 7A




Figure 7B




Figure 8




Figure 9




Figure 10

Figure 11

Hematological changes induced by Oxaliplatin \pm MSC in nude mice on day 5 after Oxaliplatin treatment

Treatment	WBC	RBC	HGB	HCT	MCV	MCH	MCHC	PLT
Control	2.69 \pm 1.6	8.75 \pm 0.9	14.9 \pm 1.4	46.7 \pm 4.1	53.3 \pm 0.9	17.1 \pm 0.4	32.0 \pm 0.2	972 \pm 166
MSC(0.2)*	3.45 \pm 2.4	8.30 \pm 0.8	14.0 \pm 1.4	44.8 \pm 4.2	54.0 \pm 1.2	16.8 \pm 0.4	31.2 \pm 0.5	1305 \pm 233
Oxaliplatin(15)**	0.90 \pm 0.8	7.49 \pm 0.6	12.7 \pm 0.9	39.5 \pm 3.0	52.8 \pm 0.9	17.0 \pm 0.4	32.3 \pm 0.8	605 \pm 75
MSC(0.2)* + Oxaliplatin(15)**	2.91 \pm 1.6	7.10 \pm 1.1	12.3 \pm 1.9	38.4 \pm 5.7	54.1 \pm 1.3	17.4 \pm 0.1	32.1 \pm 0.8	922 \pm 214

Figure 12

White blood cells and platelets changes induced by Oxaliplatin ± MSC in nude mice

Treatment	White Blood Cells		Neutrophils		Platelets	
	#(1000/CU MM)	% Control	#(1000/CU MM)	% Control	#(1000/CU MM)	% Control
Control	2.69 ± 1.6	100 %	0.75 ± 0.31	100 %	972 ± 166	100 %
MSC(0.2)	3.45 ± 2.4	128 %	0.97 ± 0.30	129 %	1305 ± 233	134 %
Oxaliplatin(15)	0.90 ± 0.8	33 %	0.19 ± 0.10	25 %	605 ± 75	62 %
MSC(0.2) + Oxaliplatin(15)	2.91 ± 1.6	108 %	0.85 ± 0.50	113 %	922 ± 214	95 %

Figure 13

Differential WBC counts (%) in nude mice on day 5 after Oxaliplatin ± MSC treatment

Treatment	Neutrophils	Lymphocytes	Monocytes	Eosinophils	Basophils	LUC
Control	27.9 ± 11.4	52.5 ± 18.8	0.78 ± 0.31	1.2 ± 0.5	2.90 ± 1.3	15.2 ± 19.1
MSC(0.2)	28.2 ± 8.7	64.1 ± 4.9	0.40 ± 0.29	1.1 ± 0.5	0.98 ± 0.4	5.2 ± 6.9
Oxaliplatin (15)	21.4 ± 11.0	65.0 ± 12.8	0.46 ± 0.54	1.4 ± 2.3	1.60 ± 1.3	9.9 ± 9.0
MSC (0.2) + Oxaliplatin (15)	29.2 ± 17.4	48.2 ± 6.1	1.94 ± 1.84	1.1 ± 0.5	2.10 ± 1.7	19.4 ± 17.2